NCI Cancer Bulletin: A Trusted Source for Cancer Research News
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
September 13, 2005 • Volume 2 / Number 35 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Community Clinical Oncology Programs (CCOPs)

Christiana Care Health ServicesNorthern New Jersey CCOPNorth Shore Community Clinical Oncology ProgramGeisinger Health SystemMain Line Health CCOPHematology-Oncology Associates of Central New YorkIowa Oncology Research AssociationDC United MB-CCOPOur Lady of Mercy Comprehensive Cancer Center MB-CCOPCedar Rapids Oncology Project CCOPIllinois Oncology Research Association CCOPCarle Cancer Center Evanston Northwestern HealthcareCentral Illinois Community Clinical Oncology ProgramNorthern Indiana Cancer Research ConsortiumWichita Community Clinical Oncology ProgramGrand Rapids Clinical Oncology ProgramKalamazoo CCOPMichigan Cancer Research Consortium CCOPBeaumont Community Clinical Oncology ProgramMetro-Minnesota Community Clinical Oncology ProgramDuluth CCOPSt. Louis-Cape Girardeau CCOPKansas City Clinical Oncology ProgramCancer Research for the OzarksHeartland Cancer Research CCOPMeritCare Hospital CCOPMissouri Valley Cancer ConsortiumDayton Clinical Oncology ProgramColumbus Community Clinical Oncology ProgramToledo Community Hospital Oncology ProgramSioux Community Cancer Consortium Marshfield Community Clinical Oncology ProgramSt. Vincent Regional Cancer Center CCOPUniversity of Illinois at Chicago MB-CCOPJohn H. Stroger, Jr., Hospital of Cook County MB-CCOPBay Area Tumor Institute CCOPSanta Rosa Memorial Hospital CCOPSouthern Nevada Cancer Research Foundation CCOPColumbia River Oncology ProgramVirginia Mason CCOPNorthwest CCOPWestern Regional Community Clinical Oncology ProgramCancer Research Center of Hawaii MB-CCOPColorado Cancer Research ProgramMontana Cancer Consortium CCOPUniversity of New Mexico Cancer Research & Treatment CenterFlorida Pediatric Community Clinical Oncology ProgramMount Sinai Community Clinical Oncology ProgramAtlanta Regional Community Clinical Oncology ProgramOchsner CCOPSoutheast Cancer Control Consortium, Inc., CCOPOklahoma CCOPUpstate Carolina CCOPGreenville CCOPScott & White Center for Cancer Prevention and CareThe Gulf Coast MB-CCOPMedical College of GeorgiaLSU Health Sciences Center Stanley S. Scott Cancer Center MB-CCOPSan Juan MBCCOPMeharry Medical CollegeSouth Texas Pediatric MB-CCOPVirginia Commonwealth University MB-CCOP
CCOPs Facts

There are 3,675 physicians in the CCOPs, ranging from 2 to 132 per program.

There are 415 hospitals participating in the CCOPs, ranging from 1 to 23 per program.

There are 68 active prevention and control trials and 283 active treatment trials in the CCOPs network.

The Study of Tamoxifen and Raloxifene (STAR), one of the largest breast cancer prevention studies ever conducted, completed recruitment in October 2004 with 19,747 women, 6,579 at CCOP sites (33 percent). The Southeast Cancer Control Consortium CCOP was the top accruer to STAR.

Although Minority-based CCOPs make up less than 20 percent of CCOP grantees, they contribute 33 percent of the network's minority accruals and 7 percent of minority patients on all cooperative group trials.

The most common symptoms addressed in CCOP symptom-management trials are pain, anorexia, mucositis, neuropathy, and hot flashes.

The primary NCI mechanism for conducting phase III clinical trials in symptom management, palliative care, and other cancer control issues is the CCOP Network.

Since 1982, CCOPs have enrolled 104,160 patients - approximately 1/3 of all NCI treatment trial participants - to NCI-sponsored treatment clinical trials.

One of the first clinical trials to show cancer-preventive effects of aspirin was the CCOP-conducted Colorectal Adenoma Prevention Study in 2003, after several epidemiologic studies linked such non-steroidal anti-inflammatory drugs to lower rates of colorectal adenomas (polyps).


Map Key

CCOPs (50)
Minority-based CCOPs (13)

The Selenium and Vitamin E Cancer Prevention Trial (SELECT), an ongoing study of dietary supplements in prostate cancer prevention, enrolled 35,534 men in 3 years; 10,270 (29 percent) of these at CCOP sites. The Upstate Carolina CCOP was the second top accruer overall to SELECT and the University of Illinois at Chicago MB-CCOP was the top accruer of African-American men to the study.

Since 1990, prevention clinical trials conducted by the CCOP Program have enrolled 92,300 people who are at risk for cancer.

The first large-scale prevention trial to use the CCOP network was the Breast Cancer Prevention Trial testing tamoxifen in 1992. More than 13,388 women joined in just 4 years, 4,087 of them at CCOPs (30.5 percent).

Tamoxifen, which in 1998 was the first drug approved by the FDA for cancer risk reduction, was approved based on the results of the CCOP-conducted Breast Cancer Prevention Trial.

The CCOP-conducted Prostate Cancer Prevention Trial (PCPT) enrolled 18,882 participants - 7,312 from CCOP sites (38.7 percent). The drug studied, finasteride, is the first drug found to reduce the risk of prostate cancer.